Skip to content
‹ Back to IndustriesSciences

There Aren’t That Many Women in AI Fields, Both in Reality and in Film. What Needs to Change?

Around the world, women make up less than a quarter of the AI workforce. This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood. According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education. Experts believe that the…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By carey.scott · · AvengersBechdel TestEx MachinaGender Pay Gap
Share

Key takeaways

01

Around the world, women make up less than a quarter of the AI workforce.

02

This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood.

03

According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Around the world, women make up less than a quarter of the AI workforce. This data, shared by the World Economic Forum (WEF), is indicative of a bias that starts in childhood. According to the WEF, reasons like societal and cultural norms can lead to fewer women taking up STEM education. Experts believe that the number of women in AI will only increase when equal opportunities are created for women.

Life imitates art and art imitates life, right? The notion applies to women’s representation in the data science field, too; the WEF’s unfortunate statistic is present even in media content. A study, conducted by Cambridge University researchers, found that barely 8% of AI professionals depicted in popular movies between 1920 and 2020 were women. As many as 1,400 films on AI were reviewed as part of the study, out of which 142 influential films were finally analyzed. A total of 116 AI professionals were identified, of which just nine were female. Prominent movies that were analyzed included Ex Machina, released in 2014, and those from the Avengers franchise.

Dr. Natalie’s Thoughts:

Dr. Natalie Morse, a senior data scientist at Torqata Data and Analytics, discussed why universal childcare and formalized federal parental leave policies could go a long way in changing the current statistics on women in AI and other STEM fields.

“It’s important that we have women represented in film. It is, but it’s more important that we actually create spaces where women can be successful in AI, in tech, in all fields. So, I have been the only female on an all-men tech team where we did R&D focused on AI. It was a Fortune 500 company. It was awesome. The main qualification for being in that room was having your PhD in Computer Science. Same for these films, right? All these tech geniuses, they’ve got their PhDs because you don’t just wake up and become an AI genius. In the US, we graduate about 3,500 PhDs in this space every year, and only 30% are female. So about 850 women each year even have the potential to become these AI leaders and geniuses. The number’s gone up about 6% in the last five years. But it’s still not 50-50 or anywhere close.

So, why are less females going into this space? Let me tell you a story. So I’ve got friends that are married. They’re doctors, they have children. Doctor number one works full-time, doctor number two works part-time. Doctor number one is has even said, “I would actually really like you not to work because it would make my life so much easier.” Guess which one is male and which one is female? Yeah, I think you know, and this story plays out again and again over every kitchen counter in the US, right? Either explicitly or implicitly.

So, why would women go through all this hoopla to get this big degree that’s hard, that’s a PhD, if in five years, they’re expected to become a caretaker anyway? So, that is the bigger problem that tech is up against. We’re asking tech to solve a problem that is bigger than tech, right? It is a cultural problem in the US, right? Tech, politics, finance, medicine, all male-dominated fields and all things that we’re trying to solve, but we’re not actually solving the issue. So, I would love to see more women in film. I would really love to see policies that actually make it okay for women to succeed in industries. That means maybe pay parental leave, maybe childcare for children under five, expanded elder care. All of these things need to exist for women to be successful in AI or any field.”

Rhonda’s Thoughts:

Rhonda Dibachi, CEO of HeyScottie, an AI-enabled and cloud-based service for finishing services, gives her take on STEM numbers in the last 5 years and in her lifetime and where to look for inspiration for needed change.

“I think the stigma has lessened. I think it’s easier for women to be accepted and be attracted to science careers and STEM careers in general. If you take a look at the U.S. Census Bureau statistics in 1970, only 8% of STEM workforce were women. In 2019, that number had risen to 27%, so that’s good. Even though it’s 50 years, it’s within my lifetime and I’ve seen it. So, I like the direction, I like the way it’s going. If you see some young woman who is still having that stigma keeping her from her full potential, I would suggest that she look to role models, and I would suggest that she’d go to Hollywood to see some role models of strong, smart STEM-smart women, because there’s tons of them now, and there didn’t used to be when I was growing up.”

Article by Aarushi Maheshwari & Sonya Young.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

C
carey.scott
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

C
carey.scott

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512